Impact of Cancer Treatment on Fall Risk and Quality of Life
Fall Risk and Quality of Life: Influence of Dual Task Performance, Cognition, and Sensorimotor Variables in Individuals With Cancer Treatment Related Peripheral Neuropathy.
This study looks at how nerve damage from cancer treatments affects the risk of falling and quality of life for cancer survivors who have this side effect.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Texas Woman's University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT06313359 on ClinicalTrials.gov |
What this trial studies
This research examines how peripheral neuropathy, a common side effect of cancer treatments, affects fall risk and quality of life in cancer survivors. The study focuses on individuals diagnosed with non-central nervous system cancers who experience symptoms of peripheral neuropathy. Investigators will assess cognitive impairments and difficulties with physical activities that may contribute to falls or affect daily living. Participants will be compared to a control group without peripheral neuropathy to better understand these impacts.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older diagnosed with non-CNS cancer who exhibit symptoms of peripheral neuropathy.
Not a fit: Patients with diabetic peripheral neuropathy or those unable to understand English may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for cancer survivors experiencing peripheral neuropathy, enhancing their quality of life and reducing fall risks.
How similar studies have performed: Other studies have indicated that cognitive impairments and peripheral neuropathy significantly affect cancer survivors, suggesting that this approach is relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Experimental group * Individuals 18 years and older * diagnosed with non- CNS cancer who underwent treatment and presents with peripheral neuropathy symptoms. Control group * age (+/- one year) and gender matched individuals * no diagnosed peripheral neuropathy * No diagnosed cognitive symptoms. Exclusion Criteria: * Unable to follow two step commands. * Unable to ambulate x 50 feet independently without use of an assistive device. * Unable to use a phone to send text messages. * Diagnosis of diabetic peripheral neuropathy * Diagnosis of CNS cancer. * Unable to speak/understand English
Where this trial is running
Dallas, Texas
- Texas Woman's University — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Priya Karakkattil, PhD — Texas Woman's University
- Study coordinator: Priya Karakkattil
- Email: Pkarakkattil@twu.edu
- Phone: 12148625624
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.